Biomarker-driven maintenance therapy in extensive-stage-small cell lung cancer: evaluating the SWOG S1929 clinical trial Authors: Tiffany Johnston, Daniel Breadner, Jacques Raphael Published: 2026 Introduction Small cell lung cancer (SCLC) remains one of the most aggressive and difficult to successfully treat solid malignancies (1). Representing approximately 15% of lung cancers, the majority of patients present with extensive-stage disease (ES-SCLC), characterized by rapid proliferation, early dissemination, and high relapse rates. For decades, platinum-etoposide chemotherapy was the mainstay treatment, yielding a median overall survival (OS) of approximately 9–10 months (2,3). The addition of programmed death ligand-1 (PD-L1) inhibitors, atezolizumab or durvalumab, to induction platinum-etoposide has modestly improved OS by approximately two months establishing chemoimmunotherapy as standard of care (4,5). Despite high initial response rates, most patients experience disease progression shortly after transitioning to maintenance immunotherapy. The maintenance phase therefore represents a critical therapeutic inflection point marked by an opportunity to improve the durability of disease control. Against this clinical backdrop, strategies aimed at intensifying maintenance therapy have emerged. Within this evolving landscape, we provide our commentary on the S1929 trial. This was a prospective, randomized, open-label, phase II trial evaluating maintenance atezolizumab with or without the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib in patients with Schlafen 11 (SLFN11)-positive ES-SCLC (6). A total of 106 patients who had not progressed following induction platinum-etoposide plus atezolizumab were randomized. The addition of talazoparib resulted in a statistically significant improvement in median progression-free survival (PFS) [2.9 vs. 2.4 months; hazard ratio (HR) 0.66, 80% confidence interval (CI): 0.50–0.86], although no difference in OS was observed. Maintenance PD-L1 inhibition after induction with platinum etoposide and anti-PD-L1 immunotherapy became the standard with the CASPIAN and IMpower-133 trials (7,8). However, randomized data evaluating maintenance intensification have introduced new therapeutic considerations. The phase III IMforte trial demonstrated that the addition of lurbinectedin to maintenance atezolizumab improved both OS and PFS, meeting its primary endpoint (9). In parallel, the delta-like ligand 3 (DLL3)-targeting T-cell engager, tarlatamab, was evaluated in DeLLphi-303, as an add-on to maintenance PD-L1 immunotherapy (10). Although DeLLphi-303 is a phase I study and its findings are preliminary, the combination of tarlatamab with PD-L1 inhibition in the maintenance setting was shown to be feasible and safe, meeting the trial’s primary endpoint, with an encouraging signal of efficacy. To contextualize S1929 within the evolving maintenance space, we summarize selected contemporary trials evaluating maintenance intensification strategies in Table 1. These studies differ substantially in phase, design, biomarker selection, and therefore should not be directly compared. Rather, the table illustrates the diversity of approaches currently under investigation as the field seeks to improve durability of response following induction chemo-immunotherapy. In this dynamic setting, the central question that remains is how best to achieve durable disease control in the maintenance setting with an acceptable quality of life. Table 1Studies evaluating maintenance or maintenance-intensification strategies in ES-SCLCItemsS1929 DeLLphi-303IMforteTrial phasePhase IIPhase IbPhase IIIDesignRandomized, open-labelNon-randomized, open-labelRandomized, open-labelPopulationSLFN11-positive ES-SCLC; ECOG† 0–2; no progression after ≥2 cycles platinum-etoposide + atezolizumabES-SCLC; ECOG 0–1; after 4–6 cycles platinum-etoposide + PD-L1 inhibitorES-SCLC; ECOG 0–1; ongoing response or stable disease after 4 cycles atezolizumab + carboplatin + etoposide Biomarker selectionSLFN11-positive NoneNoneExperimental strategyAtezolizumab ± talazoparibTarlatamab + atezolizumab or durvalumab Lurbinectedin ± atezolizumabMedian PFSAT‡: 2.9 months; A§: 2.4 months; HR 0.665.6 months; single-arm estimateLA¶: 5.4 months; A: 2.1 months; HR 0.54OSAT: 9.7 months; A: 9.5 months; no significant difference25.3 months; early-phase estimate LA: 13.2 months; A: 10.6 months; HR 0.73†, ECOG performance status [0–5]. ‡, atezolizumab plus talazoparib. §, atezolizumab monotherapy. ¶, lurbinectedin plus atezolizumab. ECOG, Eastern Cooperative Oncology Group; ES-SCLC, extensive-stage-small cell lung cancer; HR, hazard ratio; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival. Studies evaluating maintenance or maintenance-intensification strategies in ES-SCLC †, ECOG performance status [0–5]. ‡, atezolizumab plus talazoparib. §, atezolizumab monotherapy. ¶, lurbinectedin plus atezolizumab. ECOG, Eastern Cooperative Oncology Group; ES-SCLC, extensive-stage-small cell lung cancer; HR, hazard ratio; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival. SCLC is characterized by profound genomic instability and reliance on DNA damage response pathways, creating vulnerability that can be therapeutically exploited (1). PARP inhibitors leverage this by inducing synthetic lethality in the setting of replication stress, and elevated PARP1 expression has been described in SCLC tumours (11,12). SLFN11 regulates replication fork progression and DNA damage response and has emerged as a potential predictive biomarker of PARP inhibitor sensitivity in SCLC (13-15). Prior data suggest improved outcomes in SLFN11-positive tumours treated with PARP inhibitors (13,14). S1929 introduces a biomarker-driven strategy by prospectively enrolling patients with SLFN11-positive tumours, representing one of the first randomized SCLC trials to incorporated molecular selection and demonstrate the feasibility of real-time biomarker testing. Whether this biomarker-driven approach meaningfully advances clinical outcomes, and how it should be interpreted within the increasingly competitive maintenance landscape, warrants careful discussion. Discussion S1929 addresses a clinically relevant and timely question: whether the addition of a PARP inhibitor to maintenance immunotherapy can improve outcomes in ES-SCLC when guided by biomarker selection (6). A major strength of the study lies in its biologically informed patient selection. By restricting enrollment to SLFN11-positive tumors, the investigators sought to enrich for a population more likely to benefit from PARP inhibition. Although SLFN11 remains an exploratory biomarker, S1929 demonstrates the practical feasibility of real-time biomarker testing in ES-SCLC. Of 106 patients enrolled, 105 had evaluable SLFN11 results, with a high positivity rate and a rapid turnaround time of approximately five days. Notably, biomarker assessment was conducted during induction therapy, avoiding delays in maintenance initiation. Tumour tissue was successfully obtained from routine needle core biopsies or fine-needle aspirations, directly addressing the longstanding concerns regarding limited tissue availability in SCLC. Collectively, these operational findings directly challenge the long-held assumption that molecular stratification is impractical in this aggressive disease. Notably, exploratory analyses applying higher SLFN11 H-score thresholds did not demonstrate a statistically significant difference in treatment effect. These findings suggest that increasing quantitative cutoffs may not meaningfully enhance predictive enrichment beyond the binary SLFN11-positive definition used for trial eligibility (H-score ≥1). If validated in future studies, a simplified approach to SLFN11 scoring would be easier to implement. However, further work will be required to clarify optimal assay thresholds, reproducibility, and establish external validity of SLFN11 as a predictive biomarker in ES-SCLC. Despite this conceptual strength, the magnitude of clinical benefit warrants careful scrutiny. While the trial met its primary endpoint, the observed improvement in PFS was modest—an absolute difference of 0.5 months. Moreover, this did not translate into an OS benefit which remains the most clinically meaningful outcome. It is also important to consider the potential influence of subsequent therapies administered after progression. In S1929, approximately half of patients received post-progression treatment, most commonly lurbinectedin and atezolizumab. Although no significant imbalance in study arms was reported, a higher proportion of patients in the control arm received lurbinectedin, which could potentially dilute differences in OS between treatment groups. In a disease characterized by rapid relapse and short post-progression survival, the clinical relevance of small PFS gains must be weighed carefully against toxicity burden and financial costs associated with both treatment and toxicity management. The addition of talazoparib was associated with a substantially higher incidence of grade ≥3 hematologic adverse events (50% vs. 4%; P<0.001), while non-hematologic toxicities were comparable between arms. Despite the substantial increase in reported hematologic adverse events, no differences in treatment discontinuation were observed between the two arms. However, quality of life was not directly assessed in S1929, limiting a comprehensive understanding of how these toxicities may affect functional status and patient experience during the maintenance phase. These findings raise important considerations regarding tolerability and quality of life in the maintenance setting. The statistical assumptions underlying S1929 further contextualize the findings. The trial was powered to detect an HR of 0.56, corresponding to an anticipated improvement in median PFS from approximately four to seven months. In practice, however, the control arm PFS was shorter than expected (2.4 months), and the observed HR of 0.66 reflected a more modest treatment effect. Although the study achieved statistical significance within its predefined parameters, the discrepancy between anticipated and observed benefit underscores the need for cautious interpretation. Subgroup analyses provide hypothesis-generating signals, including potential greater benefit among patients with prior radiation exposure. This observation raises an intriguing biological question regarding whether radiation-induced DNA damage may prime tumours to enhanced sensitivity to combined PARP inhibition and immunotherapy. However, these exploratory findings are underpowered and should not inform clinical practice without further prospective validation. Future clinical trials and translational work should specifically evaluate these clinically relevant subgroups in adequately powered designs, incorporating stratified randomization or pre-specified subgroup analyses to determine whether prior radiation exposure or central nervous system involvement influences treatment response. Such efforts may help refine patient selection and clarify whether certain biological or clinical contexts amplify the benefit of combined PARP inhibition and immunotherapy. When considered alongside other maintenance intensification strategies, the magnitude of benefit observed in S1929 appears modest. Phase III data from IMforte demonstrated larger improvements in PFS alongside an OS benefit, while DLL3-directed therapies such as tarlatamab represent a mechanistically distinct approach currently under evaluation (9,10). Although cross-trial comparisons are inherently limited by differences in study design and patient populations, these data provide important context for interpreting the clinical significance of S1929 within an evolving and increasingly competitive maintenance landscape. Future studies should consider the direct comparison of these maintenance strategies, including biomarker-guided approaches, to better define which strategies yield the most durable disease control in ES-SCLC. While S1929 does not immediately change clinical practice, it establishes an important foundation for biomarker-driven maintenance strategies in ES-SCLC. Future studies should build on the proof-of-concept established by S1929 by refining biomarker selection and optimizing combination strategies. This includes validating SLFN11 as a predictive biomarker in larger, prospective cohorts and standardizing assay methodologies and thresholds to ensure reproducibility across clinical settings. Additionally, rational combination strategies that enhance PARP inhibitor efficacy while mitigating hematologic toxicity, such as alternative dosing strategies or novel agents, warrant further investigation. Incorporation of patient-reported outcomes will be essential to better characterize the tolerability of intensified maintenance approaches. Ultimately, adequately powered randomized trials with OS as a primary endpoint will be critical to determine whether this biomarker-guided approach can translate into durable and clinically meaningful improvements in survival in ES-SCLC. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article has undergone external peer review. Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0607/coif). D.B. has received honoraria for consultancies from Boehringer Ingelheim, Amgen, Merck, Roche, AstraZeneca and ImmunityBio. J.R. has received honoraria from CDA-AMC as a clinical expert. The other author has no conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0607/prf Supplementary Materials The article’s supplementary files as